Clinical trials: Grippe, open to volunteers
Corona Virus Infection, Flu Vaccine
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19…
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Trial name
- NCT04579588
- Testing
- Flu shot
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Stanford University
Impact of Vaccination
Intranasal LAIV Mucosal Immunity Examination
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines.
- Trial name
- NCT07093281
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Healthy Young Adults, Influenza Vaccines
Characterizing the Human Airway Immune Response to FluMist Vaccination
The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine.
- Conditions
- Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response
- Trial name
- EVax-3 (NCT07177417)
- Testing
- FluMist, inactivated influenza vaccine, bronchoscopy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID -19, COVID - 19
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up.
- Conditions
- COVID -19, COVID - 19, COVID 19, Influenza
- Trial name
- CIRV2 (NCT07287137)
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Chronic Kidney Disease Requiring Chronic Dialysis, Vaccine Response
Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
The aim of this observational study is to determine if and how kidney failure affects the development of protective immune responses following vaccination in patients on chronic dialysis.
- Trial name
- Tfh-CKD (NCT06635525)
- Testing
- Influenza vaccination, SARS-CoV-2 vaccine
- Where
- 3 sites in Italy
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteer
Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
This is a Phase 1b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and food effect of single oral doses of TRX-100 tablets and capsules in healthy adult volunteers.
- Trial name
- NCT07526506
- Testing
- TRX-100
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Influenza
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine…
- Trial name
- NCT07302256
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine, Phosphate buffer solution (PBS)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza, Immunosenescence
Effect of Oral Supplement on Influenza Vaccine Long-term Response
This is a follow-up study of a previously completed randomized controlled trial (NCT06827873) that investigated the effects of oral supplements on influenza vaccine response in adults aged 60-70 years.
- Trial name
- EOSIIVE-F (NCT07357467)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tsinghua University
Produce and Evaluate an Evidence-based Health Awareness Video
Production and Evaluation of an Evidence-based Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases (HAV-RID Study)
Health awareness videos are integral in disseminating knowledge about respiratory infectious diseases (RIDs). The aim of this study is to produce and evaluate an evidence-based health awareness video on precautionary measures…
- Trial name
- (HAV-RID) (NCT07248319)
- Testing
- Health awareness video on precautionary measures against respiratory infectious disease
- Where
- Lebanon
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Lebanese American University
Influenza Immunization, Healthy Volunteers
Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice…
- Trial name
- NCT07282795
- Testing
- Efluelda® Pre-filled syringe
- Where
- 15 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years.
- Trial name
- NCT07169318
- Testing
- VNT-101
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccine Response
Effect of Oral Supplements for Influenza Vaccine Response
The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are: 1.
- Trial name
- EOSIIVE-RCT (NCT06827873)
- Testing
- ARA (Arachidonic Acid) Supplementation, TUDCA (Tauroursodeoxycholic Acid) Supplementation, Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tsinghua University
Influenza -Like Illness, Influenza (Healthy Volunteers)
Mucosal and Systemic Immunity Correlates of Protection Against Influenza in Young Children, Aged 2-5 Years (MUSIC-Flu)
Title: Mucosal and systemic immunity correlates of protection against influenza in young children (MUSIC-Flu). The goal of this observational study is to better understand how immune responses in the blood and mucosa are linked…
- Trial name
- MUSIC-Flu (NCT07861854)
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute for Communicable Diseases, South Africa
Influenza, Immunization
Influenza Immunization in Adults Over Age 75
The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older.
- Conditions
- Influenza, Immunization, Older Adults, Over Age 75
- Trial name
- NCT02200276
- Testing
- Influenza
- Where
- United States
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Influenza
GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE
This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a…
- Trial name
- GERMINATE (NCT06620185)
- Testing
- FLUENZ, Influenza challenge virus
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Respiratory Infection Virus, COVID -19
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their…
- Conditions
- Respiratory Infection Virus, COVID -19, RSV, FLU
- Trial name
- PREVENT (NCT07147517)
- Testing
- Component A0, Component A1, Component A2
- Where
- 2 sites in United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Influenza
A/Texas Flu Challenge
This study is designed to help us better understand how the immune system responds to the flu and how flu is transmitted in the environment.
- Trial name
- NCT06753474
- Testing
- Influenza Virus influenza A H3N2 strain
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza, Human
BPL-1357 Against H1N1 Influenza Virus Challenge
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it.
- Trial name
- NCT07215858
- Testing
- BPL-1357 IM, BPL-1357 IN
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi